Physician profile
Mallory Cast
NPI 1588235311
$1,625.99
in general payments reported to CMS, 2019-2025
27 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $563 · 2024: $774 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482 · Travel and Lodging: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.51 |
| Travel and Lodging | $144.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $275.50 | 2023-2024 | |
| Medtronic, INC. | $262.04 | 2023 | Intellis Adaptivestim, Synchromedii |
| Azurity Pharmaceuticals, INC. | $156.07 | 2024-2025 | Horizant |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.81 | 2023-2024 | Relistor |
| Curonix LLC | $99.55 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biogen, INC. | $87.64 | 2025 | Vumerity, Tysabri, Avonex |
| Collegium Pharmaceutical, INC. | $78.84 | 2024-2025 | Belbuca, Xtampza |
| Lilly USA, LLC | $74.97 | 2023 | Reyvow, Emgality |
| Ucb, INC. | $55.10 | 2024 | Briviact, Rystiggo |
| Stryker Corporation | $41.30 | 2025 | Aequalis Perform Reversed |
| Averitas Pharma INC. | $38.71 | 2024-2025 | Qutenza |
| Catalyst Pharmaceuticals, INC. | $36.79 | 2024 | |
| Pfizer INC. | $35.18 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $28.35 | 2025 | |
| Impel Pharmaceuticals INC. | $25.14 | 2023 | Trudhesa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $22.68 | 2023 | Vyepti |
| Smith+Nephew, INC. | $21.38 | 2025 | "Acticoat 4"" X 4""", Pico |
| Upsher-Smith Laboratories LLC | $18.84 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $18.52 | 2023 | Austedo Xr |
| Merz Pharmaceuticals, LLC | $18.48 | 2025 | Xeomin, Inbrija |
| Nevro Corp. | $17.51 | 2024 | Senza |
| Neurocrine Biosciences, INC. | $17.42 | 2023 | |
| Scilex Pharmaceuticals INC. | $16.99 | 2024 | |
| Amneal Pharmaceuticals LLC | $16.96 | 2023 | Rytary |
| Ferring Pharmaceuticals INC. | $16.07 | 2025 | Euflexxa |
| Janssen Pharmaceuticals, INC | $15.52 | 2024 | Spravato |
| Axsome Therapeutics, INC. | $14.63 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Cast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.